Importantly, concomitant inactivation of RB1 and TP53 in pre-treatment adenocarcinoma strongly predicted subsequent SCLC transformation (odds ratio 131, 95% CI 19.9–859). This evidence concerns the gene RB1 and small cell lung carcinoma.